Niclosamide for Mild to Moderate COVID-19

• Status: Completed
• Trial end date: 2021-08-19
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tufts Medical Center
• Treatments: Niclosamide

Criteria

Inclusion Criteria:

• Positive SARS-CoV-2 test by PCR

• No requirement of oxygen supplementation

• Ability to take oral medication

Exclusion Criteria:

• Known allergic reactions to any components of Niclosamide medication

• Participation in another trial or use of any experimental treatment for COVID-19, including chloroquine, hydroxychloroquine, remdesivir, and lopinavir/ritonavir

• Hospitalization or requirement of hospitalization at the time of enrollment